142 related articles for article (PubMed ID: 36964091)
1. Marfan Treatment Trialists' Collaboration in perspective: Sartans and beta-blockers in patients with Marfan syndrome.
Jondeau G; Milleron O; Eliahou L; Boileau C; Ropers J
Arch Cardiovasc Dis; 2023 Apr; 116(4):173-175. PubMed ID: 36964091
[No Abstract] [Full Text] [Related]
2. Protection and delay of aortic complications in the Marfan syndrome: a new indication for angiotensin receptor blockers on top of β blockers.
Pedicino D; Volpe M
Eur Heart J; 2023 Jan; 44(4):254-255. PubMed ID: 36453082
[No Abstract] [Full Text] [Related]
3. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.
Pitcher A; Emberson J; Lacro RV; Sleeper LA; Stylianou M; Mahony L; Pearson GD; Groenink M; Mulder BJ; Zwinderman AH; De Backer J; De Paepe AM; Arbustini E; Erdem G; Jin XY; Flather MD; Mullen MJ; Child AH; Forteza A; Evangelista A; Chiu HH; Wu MH; Sandor G; Bhatt AB; Creager MA; Devereux RB; Loeys B; Forfar JC; Neubauer S; Watkins H; Boileau C; Jondeau G; Dietz HC; Baigent C
Am Heart J; 2015 May; 169(5):605-12. PubMed ID: 25965707
[TBL] [Abstract][Full Text] [Related]
4. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
Mallat Z; Daugherty A
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
[No Abstract] [Full Text] [Related]
5. Medicine. Old drug, new hope for Marfan syndrome.
Travis J
Science; 2006 Apr; 312(5770):36-7. PubMed ID: 16601163
[No Abstract] [Full Text] [Related]
6. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
7. Do angiotensin receptor blockers prevent cardiac events in patients with Marfan syndrome?
Su PY; Chiu HH; Kang YN
Eur J Prev Cardiol; 2020 Dec; 27(19):2067-2068. PubMed ID: 31660748
[No Abstract] [Full Text] [Related]
8. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
Thakur V; Rankin KN; Hartling L; Mackie AS
Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
[TBL] [Abstract][Full Text] [Related]
9. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
Hofmann Bowman MA; Eagle KA; Milewicz DM
JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
[TBL] [Abstract][Full Text] [Related]
10. Medical management of aortic disease in children with Marfan syndrome.
Lindsay ME
Curr Opin Pediatr; 2018 Oct; 30(5):639-644. PubMed ID: 30036202
[TBL] [Abstract][Full Text] [Related]
11. Of Marfan's syndrome, mice, and medications.
Bowen JM; Connolly HM
N Engl J Med; 2014 Nov; 371(22):2127-8. PubMed ID: 25405389
[No Abstract] [Full Text] [Related]
12. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
Trials; 2010 Jan; 11():3. PubMed ID: 20067609
[TBL] [Abstract][Full Text] [Related]
13. Atenolol versus Losartan in Marfan's Syndrome.
Mallat Z; Tedgui A
N Engl J Med; 2015 Mar; 372(10):980. PubMed ID: 25738683
[No Abstract] [Full Text] [Related]
14. Atenolol versus Losartan in Marfan's Syndrome.
Treasure T; Pepper J; Mohiaddin R
N Engl J Med; 2015 Mar; 372(10):978-9. PubMed ID: 25738682
[No Abstract] [Full Text] [Related]
15. Atenolol versus Losartan in Marfan's Syndrome.
Ziganshin BA; Mukherjee SK; Elefteriades JA
N Engl J Med; 2015 Mar; 372(10):977-8. PubMed ID: 25738681
[No Abstract] [Full Text] [Related]
16. Atenolol versus Losartan in Marfan's Syndrome.
Lacro RV; Dietz HC; Mahony L
N Engl J Med; 2015 Mar; 372(10):980-1. PubMed ID: 25738680
[No Abstract] [Full Text] [Related]
17. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
[TBL] [Abstract][Full Text] [Related]
18. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
Singh MN; Lacro RV
Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular pharmacotherapy in patients with Marfan syndrome.
Yetman AT
Am J Cardiovasc Drugs; 2007; 7(2):117-26. PubMed ID: 17503882
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
